| Hyperforin as a possible antidepressant component of hypericum extracts SS Chatterjee, SK Bhattacharya, M Wonnemann, A Singer, WE Müller Life sciences 63 (6), 499-510, 1998 | 701 | 1998 |
| Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice S Hauptmann, I Scherping, S Dröse, U Brandt, KL Schulz, M Jendrach, ... Neurobiology of aging 30 (10), 1574-1586, 2009 | 514 | 2009 |
| Abuse and dependence potential for the non‐benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data G Hajak, WE Müller, HU Wittchen, D Pittrow, W Kirch Addiction 98 (10), 1371-1378, 2003 | 505 | 2003 |
| Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract WE Müller, A Singer, M Wonnemann, U Hafner, M Rolli, C Schäfer Pharmacopsychiatry 31 (S 1), 16-21, 1998 | 483 | 1998 |
| Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice DC David, S Hauptmann, I Scherping, K Schuessel, U Keil, P Rizzu, ... Journal of Biological Chemistry 280 (25), 23802-23814, 2005 | 467 | 2005 |
| The location of drug binding sites in human serum albumin KJ Fehske, WE Müller, U Wollert Biochemical Pharmacology 30 (7), 687-692, 1981 | 458 | 1981 |
| Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration S Gispert, F Ricciardi, A Kurz, M Azizov, HH Hoepken, D Becker, W Voos, ... PloS one 4 (6), e5777, 2009 | 440 | 2009 |
| Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity WE Müller, M Rolli, C Schäfer, U Hafner Pharmacopsychiatry 30 (S 2), 102-107, 1997 | 427 | 1997 |
| Mitochondrial dysfunction, apoptotic cell death, and Alzheimer’s disease A Eckert, U Keil, CA Marques, A Bonert, C Frey, K Schüssel, WE Müller Biochemical pharmacology 66 (8), 1627-1634, 2003 | 382 | 2003 |
| Hyperforin, a major antidepressant constituent of St. John’s Wort, inhibits serotonin uptake by elevating free intracellular Na+ 1 1 A Singer, M Wonnemann, WE Müller Journal of Pharmacology and Experimental Therapeutics 290 (3), 1363-1368, 1999 | 378 | 1999 |
| Amyloid β-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis U Keil, A Bonert, CA Marques, I Scherping, J Weyermann, ... Journal of Biological Chemistry 279 (48), 50310-50320, 2004 | 366 | 2004 |
| Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation K Leuner, T Schütt, C Kurz, SH Eckert, C Schiller, A Occhipinti, S Mai, ... Antioxidants & redox signaling 16 (12), 1421-1433, 2012 | 352 | 2012 |
| Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase D Albert, I Zündorf, T Dingermann, WE Müller, D Steinhilber, O Werz Biochemical pharmacology 64 (12), 1767-1775, 2002 | 344 | 2002 |
| Current St. John’s wort research from mode of action to clinical efficacy WE Müller Pharmacological research 47 (2), 101-109, 2003 | 343 | 2003 |
| Hyperforin—a key constituent of St. John's wort specifically activates TRPC6 channels K Leuner, V Kazanski, M Muller, K Essin, B Henke, M Gollasch, ... The FASEB Journal 21 (14), 4101-4111, 2007 | 307 | 2007 |
| ROS generation, lipid peroxidation and antioxidant enzyme activities in the aging brain S Leutner, A Eckert, WE Müller Journal of neural transmission 108, 955-967, 2001 | 298 | 2001 |
| Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer’s disease—therapeutic aspects WE Müller, A Eckert, C Kurz, GP Eckert, K Leuner Molecular neurobiology 41, 159-171, 2010 | 280 | 2010 |
| Stratified medicine for mental disorders G Schumann, EB Binder, A Holte, ER de Kloet, KJ Oedegaard, ... European Neuropsychopharmacology 24 (1), 5-50, 2014 | 273 | 2014 |
| Effects of EGb 761® Ginkgo biloba extract on mitochondrial function and oxidative stress A Eckert, U Keil, S Kreßmann, K Schindowski, S Leutner, S Leutz, ... Pharmacopsychiatry 36 (S 1), 15-23, 2003 | 247 | 2003 |
| Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‘subsyndromal’anxiety disorder: a randomized, double-blind, placebo controlled trial S Kasper, M Gastpar, WE Müller, HP Volz, HJ Möller, A Dienel, S Schläfke International clinical psychopharmacology 25 (5), 277-287, 2010 | 246 | 2010 |
